TNK-TPA is a promising fibrin-specific thrombolytic agent for acute myocardial infarction that allows for single bolus administration.
TNK-TPA has a prolonged half-life so it can be administered as a single bolus. TNK-TPA appears to be very fibrin specific, and the initial patency and safety profiles are encouraging. Further study of this new thrombolytic agent is ongoing.
Cannon et al. (Tue,) studied this question.